The objectives of the Developmental Research Projects Program are to provide a continuous flow of new ideas and projects to stimulate myeloma research in the context of the Myeloma SPORE. It encourages new research directions and methodologies and facilitates collaborations. By providing initial support to pilot projects, it will foster the development of new translational projects. It also allows the Myeloma SPORE to have participation and recruitment of new investigators not only from the DF/HCC but also from outside institutions. Our Developmental Research Program during the previous funding period was extremely successful, with three projects in this renewal SPORE application directly evolving from prior Developmental Projects. This Program will continue to rely on scientific and programmatic review by the Governance Committee, which will assure selection of the most promising, highest quality, projects with high likelihood of translational impact. To achieve this goal, we will: 1) Solicit applications and/or identify novel myeloma research projects 2) Evaluate these projects for funding, 3) Fund the most innovative developmental projects, 4) Re-evaluate projects for possible transition into full project status, and 5) Evaluate success of the program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100707-12
Application #
8764980
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$152,228
Indirect Cost
$59,283
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Perrot, Aurore; Lauwers-Cances, Valerie; Corre, Jill et al. (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456-2464
Tai, Yu-Tzu; Lin, Liang; Xing, Lijie et al. (2018) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia :
Gonsalves, Wilson I; Buadi, Francis K; Ailawadhi, Sikander et al. (2018) Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant :
Bae, J; Hideshima, T; Zhang, G L et al. (2018) Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia 32:752-764
Ye, Shuai; Lawlor, Matthew A; Rivera-Reyes, Adrian et al. (2018) YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res 78:2705-2720
Hunter, Zachary R; Xu, Lian; Tsakmaklis, Nickolas et al. (2018) Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv 2:2937-2946
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813

Showing the most recent 10 out of 407 publications